Biologic therapies in rheumatology: Lessons learned, future directions

Nature Reviews Drug Discovery

Volumn 6, Issue 1, 2007, Pages 75-92

  Strand, Vibeke ^a   Kimberly, Robert ^b   Isaacs, John D ^c  

^a STANFORD UNIVERSITY   (United States)

^b The University of Alabama at Birmingham   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BELIMUMAB; CD28 SUPERMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYTOKINE; EPRATUZUMAB; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G4; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; LENERCEPT; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCYTE CHEMOTACTIC PROTEIN 1; OKT 4; OKT 8; ORTHOCLONE; PEGSUNERCEPT; PROTEIN P55; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RICIN A; RITUXIMAB; TENEFUSE; TGN 1412; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; AUTOIMMUNITY; BIOLOGICAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SENSITIZATION; DRUG TARGETING; DRUG USE; FIRST DOSE REACTION; FLU LIKE SYNDROME; GRAFT REJECTION; GRANULOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; LUNG INFILTRATE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOCYTOTOXICITY; LYMPHOMA; MONOCYTOPENIA; MONOTHERAPY; MUCKLE WELLS SYNDROME; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; RIGOR; SEPSIS; SIDE EFFECT; SJOEGREN SYNDROME; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TACHYPHYLAXIS; THROMBOEMBOLISM; THYMUS FUNCTION; THYROID GLAND; TUBERCULOSIS; TUMOR ESCAPE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BIOLOGICAL THERAPY; CYTOKINES; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY; T-LYMPHOCYTES;

EID: 33845882484     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2196     Document Type: Review

References (232)

1. Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
2. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330-337 (2004).
3. Padyukov, L., Silva, C., Stolt, P., Alfredsson, L. & Klareskog, L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50, 3085-3092 (2004).
4. Klareskog, L. et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54, 38-46 (2006).
5. Marshall, E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311, 1688-1689 (2006).
6. Cobbold, S., Qin, S., Leong, L., Martin, G. & Waldmann, H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129, 165-201 (1992).
7. Kremer, J. M. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 2263-2271 (2005).
8. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
9. Fishwild, D., Hudson, D., Deshpande, U. & Kung, A. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin. Immunol. 92, 138-152 (1999).
10. Mason, U. et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J. Rheumatol. 29, 220-229 (2002).
11. Black, L., Bendele, A., Bendele, R., Zack, P. & Hamilton, M. Regulatory decision strategy for entry of a novel biologic therapeutic with a clinically unmonitorible toxicity into clinical trials: Pre-IND meetings and a case example. Toxicol. Pathol. 27, 22-26 (1999).
12. Olsen, N. et al. A double blind, placebo controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum. 39, 1002-1008 (1996).
13. Isaacs, J. D. & Waldmann, H. Regaining self-control - regulation and immunotherapy. Br J. Rheumatol. 37, 926-929 (1998).
14. Piccirillo, C. A. & Shevach, E. M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: Central players in the arena of peripheral tolerance. Semin. Immunol. 16, 81-88 (2004).
15. Choy, E. et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 41, 1142-1148 (2002).
16. Gutstein, N., Seaman, W., Scott, J. & Wofsy, D. Induction of immune tolerance by administration of monoclonal antibodies to L3T4. J. Immunol. 137, 1127-1132 (1986).
17. Hale, G., Xia, M. Q., Tighe, H. P., Dyer, M. J. & Waldmann, H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35, 118-127 (1990).
18. Isaacs, J. et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748-752 (1992).
19. Isaacs, J. D. et al. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J. Rheumatol. 35, 231-240 (1996).
20. Matteson, E. L. et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38, 1187-1193 (1995).
21. Weinblatt, M. et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: An intravenous dose-escalation study. Arthritis Rheum. 38, 1589-1594 (1995).
22. Schnitzer, T. et al. Subcutaneous administration of CAMPATHT™-1H: Clinical and biological outcomes. J. Rheumatol. 24, 1031-1036 (1997).
23. Moreau, T. et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119, 225-237 (1996).
24. Wing, M., Waldmann, H., Isaacs, J., Compston, D. & Hale, G. Ex vivo whole blood cultures for predicting cytokine release syndrome: dependence on target antigen and antibody isotype. Ther. Immunol. 2, 183-190 (1995).
25. Wing, M. et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98, 2819-2826 (1996).
26. Brett, S. et al. Repopulation of blood lymphocyte subpopulations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody CAMPATH 1H. Immunol 88, 13-19 (1996).
27. Ponchel, F. et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100, 4550-4556 (2002).
28. Ponchel, F. et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res. Ther. 7, R80- R92 (2005).
29. Moreland, L. W. et al. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum. 37, 834-838 (1994).
30. Isaacs, J. et al. Morbidity and mortality in rheumatoid arthritis patients with profound and prolonged therapy-induced lymphopenia. Arthritis Rheum. 44, 1998-2008 (2001).
31. Isaacs, J. et al. Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. Arthritis Rheum. 50, S700 (2004).
32. Ruderman, E. M., Weinblatt, M. E., Thurmond, L. M., Pinkus, G. S. & Gravallese, E. M. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum. 38, 254-258 (1995).
33. Jendro, M., Ganten, T., Matteson, E., Weyand, C. & Goronzy, J. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum. 38, 1242-1250 (1995).
34. Ernst, B., Lee, D. S., Chang, J. M., Sprent, J. & Surh, C. D. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11, 173-181 (1999).
35. Coles, A. J. et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691-1695 (1999).
36. Cox, A. L. et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332-3342 (2005).
37. Isaacs, J. et al. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106, 427-433 (1996).
38. Schulze-Koops, H., Davis, L., Haverty, P., Wacholtz, M. & Lipsky, P. Reduction of Th1 cell activity in peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J. Rheumatol. 25, 2065-2076 (1998).
39. Moreland, L. et al. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis. J. Rheumatol. 25, 221-228 (1998).
40. Greenwood, J., Clark, M. & Waldmann, H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23, 1098-1104 (1993).
41. Wu, J. et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100, 1059-1070 (1997).
42. Lockwood, C., Thiru, S., Isaacs, J., Hale, G. & Waldmann, H. Long term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341, 1620-1622 (1993).
43. Stephens, S. et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85, 668-674 (1995).
44. Brett, S. et al. Emergence of CD52-, glycosylphosphati dylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Int. Immunol. 8, 325-334 (1996).
45. Beyersdorf, N. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445-455 (2005).
46. Hunig, T. & Dennehy, K. CD28 superagonists: Mode of action and therapeutic potential. Immunol. Lett. 100, 21-28 (2005).
47. Wilde, M. I. & Goa, K. L. Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 51, 865-894 (1996).
48. Ferran, C., Bach, J. F. & Chatenoud, L. In vivo T cell activation properties of anti-T cell monoclonal antibodies. Exp. Nephrol. 1, 83-89 (1993).
49. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
50. Elflein, K., Rodriguez-Palmero, M., Kerkau, T. & Hunig, T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 102, 1764-1770 (2003).
51. Marshall, E. Clinical medicine. Accident prompts a closer look at antibody trials. Science 312, 172 (2006).
52. Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613-620 (2006).
53. Looney, R. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
54. Sfikakis, P. P., Boletis, J. N. & Tsokos, G. C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: Pointing to the future. Curr. Opin. Rheumatol. 17, 550-557 (2005).
55. Cohen, S. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary safety and efficacy at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006).
56. Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
57. Edwards, J. C., Cambridge, G. & Abrahams, V. M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 97, 188-196 (1999).
58. Panayi, G. S. B cells: A fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford) 44 (Suppl. 2), ii3-ii7 (2005).
59. Edwards, J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
60. Emery P, F. D., Ferraccioli G, Udell J, Van Vollenhoven RF, Rowe K, Agarwal S, Shaw T. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann. Rheumatic Dis. 65, 58 (2006).
61. Cambridge G, L. M., Isenberg DA, Teodorescu M, Ehrenstein MR, Edwards JC. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and anti-microbial antibody profile. Arthritis and Rheumatism 50, S227- S228 (2004).
62. Roll, P., Palanichamy, A., Kneitz, C., Dorner, T. & Tony, H. P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54, 2377-2386 (2006).
63. Silverman, G. J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: Emerging patterns and paradigms. Arthritis Rheum. 54, 2356-2367 (2006).
64. Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52, 501-513 (2005).
65. Gunnarsson, I. et al. Histopathological and clinical changes in patients with severe lupus nephritis treated with rituximab plus cyclophosphamide: A rebiopsy study in 7 patients. Ann. Rheum. Dis. 65, 64 (2006).
66. Dass, S. et al. Response to rituximab therapy in RA correlates with variable B cell expression in peripheral blood and synovium. Ann. Rheum. Dis. 65, 186 (2006).
67. Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542-1545 (2005).
68. Isenberg, D. A. B cell targeted therapies in autoimmune diseases. J. Rheumatol. Suppl 77, 24-28 (2006).
69. Wallace, D. & al., e. Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS) shows bioactivity and reduces systemic lupus erythematosus disease activity. Ann. Rheum. Dis. 65, 62 (2006).
70. Furie, R. & al., e. Multiple SLE disease activity measures in a multi-centre phase 2 SLE trial demonstrate belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves ot stabilizes SLE activity. Ann. Rheum. Dis. 65, 63 (2006).
71. Dorner, T. et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006).
72. Steinfeld, S., Tant, L., Burmester, G. & al., e. Epratuzumab [humanized anti CD22 antibody] in primary Sjögren's syndrome: An open label phase I/II study:. Arthritis Res. Ther. 8, R129 (2006).
73. Pijpe, J. et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum. 52, 2740-2750 (2005).
74. Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817-826 (2005).
75. Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
76. Hamaguchi, Y. et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174, 4389-4399 (2005).
77. Seyler, T. et al. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 115, 3083-3092 (2005).
78. Fisher, C. J., Jr. et al. Treatment of septic shock with the tumor necrosis factor receptor:FC fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702 (1996).
79. Suitters, A. J. et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor α chimeric antibodies in experimental septic shock. J. Exp. Med. 179, 849-856 (1994).
80. Aderka, D., Engelmann, H., Maor, Y., Brakebusch, C. & Wallach, D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175, 323-329 (1992).
81. Bendtzen, K., Hansen, M., Ross, C., Poulsen, L. & Svenson, M. Cytokines and autoantibodies to cytokines. Stem Cells 13, 206-222 (1995).
82. Ulfgren, A. et al. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum. 43, 2391-2396 (2000).
83. De Silva, A. et al. Pharmacogenetics of infliximab in Crohn's disease: the 5q31/IBD5 risk haplotype predicts response. Gastroenterology 122, M1423 (2002).
84. Louis, E. et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with - 308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818-824 (2002).
85. Mascheretti, S. et al. Pharmacogenetic investigation of the TNF/ TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics 2, 127-136 (2002).
86. Mugnier, B. et al. Polymorphism at position - 308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48, 1849-1852 (2003).
87. Criswell, L. A. et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50, 2750-2756 (2004).
88. Tutuncu, Z. et al. Fc-γ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. Arthritis Rheum. 52, 2693-2696 (2005).
89. Anolik, J. et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459 (2003).
90. Catrina, A. et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum. 52, 61-72 (2005).
91. Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M. & Ghrayeb, J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259 (1995).
92. Ehrenstein, M. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF α therapy. J. Exp. Med. 200, 277-285 (2004).
93. Valencia, X. et al. TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood 108, 253-61 (2006).
94. Shen, C. et al. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21, 251-258 (2005).
95. Mitoma, H. et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128, 376-392 (2005).
96. Mitoma, H., Horiuchi, T. & Tsukamoto, H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α. Gastroenterology 126, 934-935; author reply 935-936 (2004).
97. Goedkoop, A. et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 63, 769-773 (2004).
98. Choy, E. H. et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41, 1133-1137 (2002).
99. Schreiber, S. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807-818 (2005).
100. Rankin, E. et al. The therapeutic effects of an engineered human anti-tumor necrosis factor α antibody (CDP571) in rheumatoid arthritis. Brit J. Rheumatol. 53, 1485-1493 (1995).
101. Sandborn, W. et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial. Gut 53, 1485-1493 (2004).
102. Zou, J. et al. Downregulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. 48, 780-790 (2003).
103. Zou, J. et al. Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis. 62, 561-564 (2003).
104. Saliu, O. Y., Sofer, C., Stein, D. S., Schwander, S. K. & Wallis, R. S. Tumor-necrosis-factor blockers: Differential effects on mycobacterial immunity. J. Infect. Dis. 194, 486-492 (2006).
105. De Rycke, L. et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantiodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 52, 2192-2201 (2005).
106. Jonsdottir, T. et al. Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. 63, 1075-1078 (2004).
107. van Vollenhoven, R., Harju, A., Brannemark, S. & Klareskog, L. Treatment with infliximab (Remicade) when etancercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis. 62, 1195-1198 (2003).
108. Hansen, K. E. et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31, 1098-1102 (2004).
109. Nikas, S. N. et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann. Rheum. Dis. 65, 257-260 (2006).
110. Buch, M. H. et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 52, 42-8 (2005).
111. Buch, M. H., B. S., Bryer, D. & Emery, P. Type of previous infliximab non-response in rheumatoid arthritis determines subsequent response to adalimumab. Arthritis and Rheumatism 52, S348 (2005).
112. Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259-262 (1993).
113. Haringman, J. J. et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387-2392 (2006).
114. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
115. Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624 (2002).
116. Hawkins, P., Bybee, A., Aganna, E. & McDermott, M. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 50, 2708-2709 (2004).
117. Fitzgerald, A., LeClercq, S., Yan, A., Homik, J. & Dinarello, C. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52, 1794-1803 (2005).
118. Genovese, M. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412-1419 (2004).
119. Marvin, J. S. & Zhu, Z. Bispecific antibodies for dual-modality cancer therapy: Killing two signaling cascades with one stone. Curr. Opin. Drug Discov. Devel. 9, 184-193 (2006).
120. Presta, L. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13, 519-525 (2003).
121. Junghans, R. P. & Anderson, C. L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl Acad. Sci. USA 93, 5512-5516 (1996).
122. Duncan, A. & Winter, G. The binding site for C1q on IgG. Nature 332, 738-740 (1988).
123. Duncan, A., Woof, J., Partridge, L., Burton, D. & Winter, G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332, 563-564 (1988).
124. Ghetie, V. et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnol. 15, 637-640 (1997).
125. Keymeulen, B. et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
126. Friend, P. J. et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68, 1632-1637 (1999).
127. Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
128. Utset, T. O. et al. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J. Rheumatol. 29, 1907-1913 (2002).
129. Bindon, C., Hale, G. & Waldmann, H. Complement activation by immunoglobulin does not depend solely on C1q binding. Eur. J. Immunol. 20, 277-282 (1990).
130. Alters, S., Sakai, K., Steinman, L. & Oi, V. Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric andti-CD4 antibodies. J. Immunol. 144, 4587-4592 (1990).
131. Isaacs, J., Clark, M., Greenwood, J. & Waldmann, H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148, 3062-71 (1992).
132. Isaacs, J., Greenwood, J. & Waldmann, H. Therapy with monoclonal antibodies II. The contribution of Fcg receptor binding and the influence of Ch1 and Ch3 domains on in vivo effector function. J. Immunol. 161, 3863-3869 (1998).
133. Bindon, C., Hale, G. & Waldmann, H. Importance of antigen specificity for complement mediated lysis by monoclonal antibodies. Eur. J. Immunol. 18, 1507-1514 (1988).
134. Xia, M., Hale, G. & Waldmann, H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 30, 1089-1096 (1993).
135. Bruggemann, M. et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361 (1987).
136. Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323-327 (1988).
137. Louis, E. et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 11, 75-76 (2005).
138. Morgan, A. W. et al. Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum. 43, 2328-2334 (2000).
139. Morgan, A. et al. Fc RIIIA-158V and rheumatoid arthritis. A confirmation study. Rheumatology 42, 528-533 (2003).
140. Blom, A. B. et al. Increased expression of Fcγ receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor α and matrix metalloproteinase. Arthritis Rheum. 48, 1002-1014 (2003).
141. Chatenoud, L. et al. Clinical use of OKT3: The role of cytokine release and xenosensitization. J. Autoimmun. 1, 631-640 (1988).
142. Tax, W. J., Tamboer, W. P., Jacobs, C. W., Frenken, L. A. & Koene, R. A. Role of polymorphic Fc receptor FcγRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 63, 106-112 (1997).
143. van der Pol, W. & van de Winkel, J. IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 48, 222-232 (1998).
144. Isaacs, J. The antiglobulin response to therapeutic antibodies. Sem. Immunol. 2, 449-456 (1990).
145. Koren, E., Zuckerman, A. & Mire-Sluis, A. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3, 349-360 (2002).
146. Pendley, C., Schantz, A. & Wagner, C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5, 172-179 (2003).
147. FDA labelling information [online], (2004).
148. Gilliland, L. et al. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162, 3663-3671 (1999).
149. Schroeder, T. et al. Antimurine antibody formation following OKT3 therapy. Transplantation 49, 48-51 (1990).
150. Patten, P. & Schellekens, H. The immunogenicity of biopharmaceuticals: lessons learned and consequences for protein drug development. Dev. Biol. 112, 81-97 (2003).
151. Hanauer, S. et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology 116, A731 (1999).
152. Reiter, C. et al. Treatment of rheumatoid arthritis with monoclonal anti-CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 34, 525-536 (1991).
153. Baslund, B., Skjoedt, H., Klausen, T. & al., e. A phase I double blind, randomized, placebo controlled study of a non-depleting fully human anti-CD4 monoclonal antibody (HuMax CD4/HM6G) in patients with active rheumatoid arthritis. Arthritis Rheum. 43, S89 (2000).
154. DeNardo, G. L., Bradt, B. M., Mirick, G. R. & DeNardo, S. J. Human antiglobulin response to foreign antibodies: Therapeutic benefit? Cancer Immunol. Immunother. 52, 309-316 (2003).
155. Cobbold, S., Rebello, P., Davies, H., Friend, P. & Clark, M. A simple method for measuring patient anti globulin responses against isotypic or idiotypic determinants. J. Immunol. Methods 127, 19 (1990).
156. Christen, U., Thuerkauf, R., Stevens, R. & Lesslauer, W. Immune response to a recombinant human TNFR55-IgGI fusion protein: Autoantibodies in rheumatoid arthritis and multiple sclerosis patients have neither neutralizing nor agonist activities. Hum. Immunol. 60, 774-790 (1999).
157. Wadhwa, M., Bird, C., Dilger, P., Gaines-Das, R. & Thorpe, R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278, 1-17 (2003).
158. Indelicato, S. Bioassays for the measurement of neutralizing antibodies in serum (SNFs). Dev. Biol. 112, 113-125 (2003).
159. Swanson, S. New technologies for the detection of antibodies to therapeutic proteins. Dev. Biol. 112, 127-133 (2003).
160. Rosenberg, A. Immunogenicity of biological therapeutics: A hierarchy of concerns. Dev. Biol. 112, 15-21 (2003).
161. Cheifetz, A. et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am. J. Gastroenterol. 98, 1315-1324 (2003).
162. Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
163. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
164. Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
165. FDA labelling information [online], (2005).
166. Ng, C., Bruno, R., Combs, D. & Davies, B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol. 45, 792-7801 (2005).
167. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
168. Gardam, M. A. et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 3, 148-155 (2003).
169. Wolfe, F., Michaud, K., Anderson, J. & Urbansky, K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50, 372-379 (2004).
170. Kollias, B. & Kontoyiannis, D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine growth Factor Rev 13, 315-321 (2002).
171. Olleros, M. L. et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 166, 1109-1120 (2005).
172. Zalevsky, J. et al. Selective inhibitor of soluble TNF blocks inflammation without suppressing innate immunity. J. Clin. Invest. (in the press).
173. Saunders, B. M. et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 174, 4852-4859 (2005).
174. Dinarello, C. Differences between anti tumor necrosis factor a monoclonal antibodies and soluble TNF receptors in host defense impairment. J. Rheumatol. 32, 40-47 (2005).
175. Dixon, W. G. et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54, 2368-2376 (2006).
176. Cope, A. P. et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94, 749-760 (1994).
177. Cope, A. P. et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185, 1573-1584 (1997).
178. Mohan, N. et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862-2869 (2001).
179. Robinson, W., Genovese, M. & Moreland, L. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 44, 1977-1983 (2001).
180. Arnett, H. A., Wang, Y., Matsushima, G. K., Suzuki, K. & Ting, J. P. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J. Neurosci. 23, 9824-9832 (2003).
181. Chung, E., Packer, M., Lo, K., Fasanmade, A. & Willerson, J. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
182. Mann, D. et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
183. Kwon, H., Coté, T., Cuffe, M., Kramer, J. & Braun, M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-111 (2003).
184. Hurlimann, D. et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
185. Wolfe, F. & Michaud, K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116, 305-311 (2004).
186. Baecklund, E., Ekbom, A., Sparen, P., Feltelius, N. & Klareskog, L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317, 180-181 (1998).
187. Askling, J. et al. Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414-1420 (2005).
188. Kalunian, K. C., Davis, J. C., Jr., Merrill, J. T., Totoritis, M. C. & Wofsy, D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 3251-3258 (2002).
189. Boumpas, D. T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003).
190. Combe, B. et al. Safety and Patient-Reported Outcomes Associated with Abatacept in the Treatment of Rheumatoid Arthritis Patients Receiving Background Disease Modifying Anti-Rheumatic Drugs (DMARDs): The ASSURE Trial. Arthritis Rheum. 52, S709 (2005).
191. Group, T. W. s. G. E. T. W. R. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
192. Carmona, L. et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766-1772 (2005).
193. Kerstan, A. & Hunig, T. Cutting edge: Distinct TCR-and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J. Immunol. 172, 1341-1345 (2004).
194. Clark, M. Antibody humanization: A case of the 'Emperor's new clothes'? Immunol. Today 21, 397-402 (2000).
195. Gorman, S. D. & Clark, M. R. Humanisation of monoclonal antibodies for therapy. Semin. Immunol. 2, 457-466 (1990).
196. Moreland, L. W. et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27, 601-609 (2000).
197. Benjamin, R., Cobbold, S., Clark, M. & Waldmann, H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163, 1539-1552 (1986).
198. Thurmond, L., Reese, M., Donaldson, R. & Orban, B. A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum. J. Pharm. Biomed. Anal. 16, 1317-138 (1998).
199. Routledge, E., Falconer, M., Pope, H., Lloyd, I. & Waldmann, H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60, 847-853 (1995).
200. Carey, G., Lisi, P. & Schroeder, T. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 60, 151 (1995).
201. Eckardt, K. & Casadevall, N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 18, 865-869 (2003).
202. Isaacs, J. D. & Waldmann, H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther. Immunol. 1, 303-312 (1994).
203. Strand, V. et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 36, 620-630 (1993).
204. Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003).
205. Targan, S. et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor for Crohn's Disease. N. Engl. J. Med. 337, 1029-1036 (1997).
206. Present, D. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405 (1999).
207. Rutgeerts, P. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999).
208. Hanauer, S. et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
209. Wolbink, G. J. et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54, 711-715 (2006).
210. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
211. McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
212. Braun, A., Takemura, S., Vallejo, A. N., Goronzy, J. J. & Weyand, C. M. Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 50, 2140-2150 (2004).
213. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356-361 (2003).
214. Herzog, C. et al. Monoclonal anti-CD4 in arthritis. Lancet 8573, 1461-1462 (1987).
215. Herzog, C. et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J. Autoimmun. 2, 627-642 (1989).
216. Goldberg, D. et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis. J. Autoimmun. 4, 617 (1991).
217. Horneff, G., Burmester, G., Emmrich, F. & Kalden, J. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 34, 129-140 (1991).
218. Horneff, G., Winkler, T., Kalden, J. R., Emmrich, F. & Burmester, G. R. Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. Clin. Immunol. Immunopathol. 59, 89-103 (1991).
219. Wendling, D. et al. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J. Rheumatol. 25, 1457-1461 (1998).
220. Moreland, L. W. et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 38, 1581-1588 (1995).
221. van der Lubbe, P. A., Dijkmans, B. A., Markusse, H. M., Nassander, U. & Breedveld, F. C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38, 1097-1106 (1995).
222. Choy, E. H., Schantz, A., Pitzalis, C., Kingsley, G. H. & Panayi, G. S. The pharmacokinetics and human antimouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody. Br J. Rheumatol. 37, 801-802 (1998).
223. Choy, E. et al. Percentage of anti CD4 monoclonal antibody coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Arthritis Rheum. 39, 52-56 (1996).
224. Yocum, D. et al. Clinical and immunologic effects of a primatized anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial. J. Rheumatol. 25, 1257-1262 (1998).
225. Hepburn, T. W., Totoritis, M. C. & Davis, C. B. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Rheumatology (Oxford) 42, 54-61 (2003).
226. Isaacs, J. et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin. Exp. Immunol. 110, 158-166 (1997).
227. Choy, E. H. et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 39, 1139-1146 (2000).
228. Nesbitt, A. & Henry, A. Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab. Ann. Rheum. Dis. 65, 456 (2006).
229. Fossati, G. & Nesbitt, A. The effect of anti-TNF agents on degranulation, necrosis and apoptosis of peripheral blood neutrophils. Gastroenterology 128, A653 (2005).
230. Nesbitt, A. & Fossati, G. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab. Ann. Rheum. Dis. 65, 455 (2006).
231. Nesbitt, A. & Fossati, G. Effect of the anti-TNF agents adalimumab, etanercept, Infliximab and certolizumab PEGol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am. J. Gastroenterol. 100, S299 (2005).
232. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).